Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Brookdale Senior Living Inc.BKD · Entity 4268 | Director | February 15, 2024 | February 20, 2024 |
| CVS HEALTH CorpCVS · Entity 2884 | Director | May 14, 2026 | May 15, 2026 |
| MAGELLAN HEALTH INCMGLN · Entity 131790 | Director | January 04, 2022 | January 04, 2022 |
| Pediatrix Medical Group, Inc.MD · Entity 4451 | Director | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Brookdale Senior Living Inc.
Report date February 15, 2024 · Filed February 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 137,262 |
Reported balance
After 2024-02-15 transaction · row 1
1 source rowRow 1 · 2024-02-15 · Grant · Acquired 23,214 · Balance 137,262 F1: Grant of unrestricted shares of Common Stock under the Amended and Restated Brookdale Senior Living Inc. 2014 Omnibus Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of unrestricted shares of Common Stock under the Amended and Restated Brookdale Senior Living Inc. 2014 Omnibus Incentive Plan.
CVS HEALTH Corp
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,106.355 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 1,447 · Balance 15,106.355 F1: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the 2017 Incentive Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the 2017 Incentive Compensation Plan.
MAGELLAN HEALTH INC
Report date January 04, 2022 · Filed January 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-01-04 transaction · row 1
1 source rowRow 1 · 2022-01-04 · Disposition to issuer · Disposed 7,973 · Balance 0 F1: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuers common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). F2: Includes 2,911 restricted shares of Common Stock. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each of these restricted shares of Common Stock was automatically cancelled and converted into the right to receive the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuers common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration").
F2: Includes 2,911 restricted shares of Common Stock. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each of these restricted shares of Common Stock was automatically cancelled and converted into the right to receive the Merger Consideration.
Pediatrix Medical Group, Inc.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 87,416 |
Reported balance
After 2026-08-12 transaction · row 1
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 472 · Balance 87,416 F1: Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to the annual equity award. Shares will vest on May 7, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to the annual equity award. Shares will vest on May 7, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Civitas Solutions, Inc.
Report date March 08, 2019 · Filed March 12, 2019
Section 16 reporting ended · disclosed 2019-03-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 1
1 source rowRow 1 · 2019-03-08 · Disposition to issuer · Disposed 37,023 · Balance 0 F1: At the effective time of the merger contemplated by the Agreement and Plan of Merger, dated as of December 18, 2018 (the "Merger Agreement"), by and among Civitas Solutions, Inc. (the "Company"), Celtic Tier II Corp. and Celtic Intermediate Corp. (the "Effective Time"), each issued and outstanding share of common stock of the Company (the "Common Stock") held by the reporting person was converted into the right to receive $17.75 in cash. Includes 7,958 restricted stock units ("RSU") that were scheduled to vest on March 9, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: At the effective time of the merger contemplated by the Agreement and Plan of Merger, dated as of December 18, 2018 (the "Merger Agreement"), by and among Civitas Solutions, Inc. (the "Company"), Celtic Tier II Corp. and Celtic Intermediate Corp. (the "Effective Time"), each issued and outstanding share of common stock of the Company (the "Common Stock") held by the reporting person was converted into the right to receive $17.75 in cash. Includes 7,958 restricted stock units ("RSU") that were scheduled to vest on March 9, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 21:00 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 472 | $26.50 | $12,508.00 |
DisclosureSEC source: 0001193125-26-352522 · ownership.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,416 F1 · kind: Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to the annual equity award. Shares will vest on May 7, 2027. Read SEC document |
| May 14, 2026 Filed May 15, 2026 21:11 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 1,447 | $97.15 | $140,576.05 |
DisclosureSEC source: 0000064803-26-000068 · form4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,106.355 F1 · kind: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the 2017 Incentive Compensation Plan. Read SEC document |
| May 07, 2026 Filed May 11, 2026 21:42 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 7,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-217242 · ownership.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,944 F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 7, 2027. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 22:46 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 1,652 | $76.04 | $125,618.08 |
DisclosureSEC source: 0000064803-25-000066 · form4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,659.355 F1 · shares: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 12:22 UTC | CVS HEALTH Corp CVS · Entity 2884 | PurchaseCommon Stock | 1,570 | $63.70 | $100,009.00 |
DisclosureSEC source: 0001127602-25-017049 · form4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,007.355 Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:50 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 2,077 | $60.47 | $125,596.19 |
DisclosureSEC source: 0001127602-25-014959 · form4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,437.355 F1 · kind: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the 2017 Incentive Compensation Plan. Read SEC document |
| May 08, 2025 Filed May 12, 2025 21:00 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 11,427 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-069430 · ownership.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,748 F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 8, 2026. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 23:07 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 2,200 | $57.10 | $125,620.00 |
DisclosureSEC source: 0001127602-24-028009 · form4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,360.355 F1 · shares: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. Read SEC document |
| May 09, 2024 Filed May 13, 2024 21:00 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 18,360 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-058786 · ownership.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,321 F1 · kind: Restricted shares granted pursupant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 9, 2025. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:09 UTC | Brookdale Senior Living Inc. BKD · Entity 4268 | GrantCommon Stock | 23,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001332349-24-000016 · wk-form4_1708466912.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,262 F1 · kind: Grant of unrestricted shares of Common Stock under the Amended and Restated Brookdale Senior Living Inc. 2014 Omnibus Incentive Plan. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:00 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 10,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029520 · doc4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,961 F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 11, 2024. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 23:06 UTC | Brookdale Senior Living Inc. BKD · Entity 4268 | GrantCommon Stock | 45,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001332349-23-000022 · wf-form4_167667516944828.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,048 F1 · kind: Grant of unrestricted shares of Common Stock under the Amended and Restated Brookdale Senior Living Inc. 2014 Omnibus Incentive Plan. Read SEC document |
| May 12, 2022 Filed May 13, 2022 21:02 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 8,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028901 · doc4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,996 F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2023. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 00:41 UTC | Brookdale Senior Living Inc. BKD · Entity 4268 | GrantCommon Stock | 24,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001332349-22-000035 · wf-form4_164488566318532.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,285 F1 · kind: Grant of unrestricted shares of Common Stock under the Amended and Restated Brookdale Senior Living Inc. 2014 Omnibus Incentive Plan. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 17:21 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Disposition to issuerOrdinary Common Stock, $0.01 par value | 7,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001004 · doc4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuers common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). F2 · kind: Includes 2,911 restricted shares of Common Stock. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each of these restricted shares of Common Stock was automatically cancelled and converted into the right to receive the Merger Consideration. F2 · shares: Includes 2,911 restricted shares of Common Stock. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each of these restricted shares of Common Stock was automatically cancelled and converted into the right to receive the Merger Consideration. F1 · price: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuers common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). F2 · price: Includes 2,911 restricted shares of Common Stock. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each of these restricted shares of Common Stock was automatically cancelled and converted into the right to receive the Merger Consideration. Read SEC document |
| August 13, 2021 Filed Aug 13, 2021 16:42 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantOrdinary Common Stock, $0.01 par value | 789 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-051412 · doc4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,973 F1 · shares: One half of the annual director restricted stock award pursuant to 2016 Management Incentive Plan. Shares shall vest fully on the first anniversary of the grant date, subject to earlier acceleration or forfeiture. F2 · price: Not applicable. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:24 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 4,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032724 · doc4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,516 F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 02:11 UTC | Brookdale Senior Living Inc. BKD · Entity 4268 | GrantCommon Stock | 26,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001332349-21-000038 · wf-form4_161421902832125.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,740 F1 · shares: Acquisition of restricted stock units under the Amended and Restated Brookdale Senior Living Inc. 2014 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation program. Each restricted stock unit will generally be payable in the form of one share of the issuer's common stock following the reporting person's termination of service as a member of the issuer's Board of Directors. Read SEC document |
| July 12, 2020 Filed Jul 15, 2020 00:24 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 11,331 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-042456 · doc4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,631 F1 · shares: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan in connection with the Reporting Person's initial appointment to the Issuer's Board of Directors. Shares will vest in three equal installments on July 12, 2021, July 12, 2022 and July 12, 2023. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 16:30 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantOrdinary Common Stock, $0.01 par value | 2,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037934 · doc4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,184 F1 · shares: Annual director restricted stock award pursuant to 2016 Management Incentive Plan. Shares shall vest fully on the date of the 2021 Annual Meeting of Shareholders. F2 · price: Not applicable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:10 UTC | Brookdale Senior Living Inc. BKD · Entity 4268 | GrantCommon Stock | 2,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001332349-20-000028 · wf-form4_158171822479281.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,218 F1 · shares: Grant of unrestricted shares of Common Stock under the Amended and Restated Brookdale Senior Living Inc. 2014 Omnibus Incentive Plan. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:59 UTC | Brookdale Senior Living Inc. BKD · Entity 4268 | GrantCommon Stock | 14,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001332349-19-000125 · wf-form4_157661996825360.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,727 F1 · shares: Grant of restricted Common Stock under the Amended and Restated Brookdale Senior Living Inc. 2014 Omnibus Incentive Plan. The shares will vest on the earlier to occur of October 29, 2020 or the date of the Company's 2020 annual meeting of stockholders, subject to continued service. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 19:40 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantOrdinary Common Stock, $0.01 par value | 2,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-038854 · doc4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,062 F1 · shares: Annual director restricted stock award pursuant to 2016 Management Incentive Plan. Shares shall vest fully on the date of the 2020 Annual Meeting of Shareholders. F2 · price: Not applicable. Read SEC document |
| May 01, 2019 Filed May 3, 2019 13:19 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantOrdinary Common Stock, $0.01 par value | 536 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-027200 · doc4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,811 F1 · shares: Pro-rated annual director restricted stock award pursuant to 2016 Management Incentive Plan. Shares shall vest fully on the date of the 2019 Annual Meeting of Shareholders. F2 · price: Not applicable. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 21:05 UTC | Civitas Solutions, Inc. CIVI · Entity 159167 | Disposition to issuerCommon Stock | 37,023 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-007269 · doc4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: At the effective time of the merger contemplated by the Agreement and Plan of Merger, dated as of December 18, 2018 (the "Merger Agreement"), by and among Civitas Solutions, Inc. (the "Company"), Celtic Tier II Corp. and Celtic Intermediate Corp. (the "Effective Time"), each issued and outstanding share of common stock of the Company (the "Common Stock") held by the reporting person was converted into the right to receive $17.75 in cash. Includes 7,958 restricted stock units ("RSU") that were scheduled to vest on March 9, 2019. F1 · price: At the effective time of the merger contemplated by the Agreement and Plan of Merger, dated as of December 18, 2018 (the "Merger Agreement"), by and among Civitas Solutions, Inc. (the "Company"), Celtic Tier II Corp. and Celtic Intermediate Corp. (the "Effective Time"), each issued and outstanding share of common stock of the Company (the "Common Stock") held by the reporting person was converted into the right to receive $17.75 in cash. Includes 7,958 restricted stock units ("RSU") that were scheduled to vest on March 9, 2019. Read SEC document |
| March 09, 2018 Filed Mar 21, 2018 23:25 UTC | Civitas Solutions, Inc. CIVI · Entity 159167 | GrantCommon Stock | 7,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021170 · doc4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,023 F1 · shares: Represents restricted stock units issued to the reporting person. The restricted stock units are subject to the terms and conditions of the Civitas Solutions, Inc. 2014 Omnibus Incentive Plan and will vest on March 9, 2019. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 23:44 UTC | Civitas Solutions, Inc. CIVI · Entity 159167 | GrantCommon Stock | 5,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-018974 · doc4.xml · nonDerivative · entry 1 SANSONE GUY P · CIK 0001301446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,065 F1 · shares: Represents restricted stock units issued to the reporting person. The restricted stock units are subject to the terms and conditions of the Civitas Solutions, Inc. 2014 Omnibus Incentive Plan and will vest on March 3, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.